Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase RNF10 (RNF10)
- Target
- RNF10
- Molecular classification
- Enzyme (E3 ubiquitin-protein ligase), DNA binding protein, Transcription factor (by some functional roles), Synaptonuclear signaling protein
01
Overview
E3 ubiquitin-protein ligase RNF10 (RNF10) is an enzyme characterized by a RING finger motif, conferring E3 ubiquitin ligase activity that targets specific ribosomal proteins (RPS2 and RPS3) during ribosome-associated quality control (RQC), especially under conditions of ribosomal stalling in translation initiation and elongation. RNF10 also functions as a transcriptional regulator, most notably enhancing the activity of the MAG promoter during Schwann cell differentiation and peripheral nerve development, and acts as a synaptonuclear messenger relaying calcium-mediated signals from NMDA receptor complexes to the nucleus in neurons. The protein is localized in the cytoplasm, synapses, and nucleus, and is evolutionarily conserved across species. While it is implicated in various biological processes such as transcriptional regulation, synaptic plasticity, and ribosome quality control, RNF10 is not currently a direct drug target, nor is it established as a disease biomarker. Its dysfunction may contribute to neurodevelopmental disorders, impaired synaptic plasticity, and abnormal protein synthesis regulation.
- Other names
- RNF10KIAA0262RIE2RING finger protein 10E3 ubiquitin-protein ligase RNF10Epididymis secretory sperm binding protein
02
Biological functions
Ubiquitination of ribosomal proteins (RPS2, RPS3) involved in ribosome-associated quality control (RQC)Regulation of myelination and Schwann cell differentiation in the nervous systemTranscriptional regulation of target genes, notably MAG in Schwann cellsSignal transduction between synapses and nucleus in neurons (synaptonuclear messenger)
03
Disease associations
Neurodegenerative disease (impaired myelination, involvement in long-term potentiation)Possibly cancer (general role in transcriptional regulation and cell proliferation, but direct evidence for RNF10 is limited)No confirmed roles in inflammation, cardiovascular disease, or infection as of current knowledge
04
Safety considerations
Disruption of RNF10 leads to defects in ribosome-associated quality control, affecting cellular protein synthesis and possibly contributing to neurodevelopmental and synaptic pathologiesKnockdown or mutation could affect myelination and neural differentiation, but no specific clinical safety concerns are documented
Beyond the preview
Go deeper on E3 ubiquitin-protein ligase RNF10 (RNF10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E3 ubiquitin-protein ligase RNF10 (RNF10).